11/18/2019 EP3081212A1 - Carboxymethylcysteine for topical treatment of stretch marks - Google Patents

 Patents carbocisteine marks 1 of 635

Back to results carbocisteine; marks;

Carboxymethylcysteine for topical treatment of stretch marks

Abstract
EP3081212A1
Carboxymethylcysteine and pharmaceutically acceptable salts thereof improve the
European Patent O ce
appearance and the structure of skin affected by stretch marks due to either pregnancy,
weight training, weight gain or adolescent growth. Carboxymethylcysteine is preferably
formulated in an appropriate topical composition and may be applied directly on the stretch Download PDF Find Prior Art Similar
marks; the composition may have a content in carboxymethylcysteine or a pharmaceutically
acceptable salt from 0.1 to 25 % by weight. Other languages: German, French

Inventor: Federico Mailland, Francesco Scarci, Giuliana Iob

Classi cations
Current Assignee : Polichem SA

A61K31/198 Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]

Worldwide applications
View 2 more classi cations
2015 EP 2016 AR WO TW

Application EP15163871.5A events

2015-04-16 Application led by Polichem SA

2015-04-16 Priority to EP15163871.5A

2016-10-19 Publication of EP3081212A1

2019-11-18 Application status is Withdrawn

Info: Patent citations (3), Non-patent citations (13), Legal

events, Similar documents, Priority and Related
Applications

External links: Espacenet, EPO GPI, EP Register, Global

Dossier, Discuss

Claims (14) Hide Dependent

1. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof, for use in the treatment of stretch marks.

2. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to claim 1, characterized in that said stretch marks are
located in any part of body or legs.

3. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to claim 1 or 2, characterized in that said stretch marks
are due to post pregnancy, weight training, weight gain or adolescent growth.

4. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to claim 1, characterized in that said pharmaceutically
acceptable salt is the lysine salt.

5. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to any of the preceding claims, characterized in that it
is used in combination with petrolatum.

6. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to any of the preceding claims, characterized in that it
is administered in the form of a pharmaceutical topical formulation, which is preferably an ointment, emulsion, cream, lotion, oil-gel, stick, massage
oil-gel or bath-oil solution.

7. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to claim 6, characterized in that said pharmaceutical
formulation has a content in carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof from 0.1 to 25 % by weight.

8. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to claim 6, characterized in that said pharmaceutical
formulation has a content in carboxymethylcysteine or a salt thereof from 0.5 to 15 % by weight.

9. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to claim 6, characterized in that said pharmaceutical
formulation has a content in carboxymethylcysteine or a salt thereof from 1.0 to 10% by weight.

https://patents.google.com/patent/EP3081212A1/en?q=carbocisteine&q=marks&oq=carbocisteine+marks 1/8
11/18/2019 EP3081212A1 - Carboxymethylcysteine for topical treatment of stretch marks - Google Patents
10. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to claim 6, characterized in that said pharmaceutical
formulation has a content in petrolatum from 1 to 35 % by weight.

11. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to claim 6, characterized in that said pharmaceutical
formulation has a content in petrolatum from 2.5 to 25 % by weight.

12. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to claim 6, characterized in that said pharmaceutical
formulation has a content in petrolatum from 5 to 20% by weight.

13. Carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof for use according to claim 6, characterized in that said pharmaceutical
formulation contains one or more physiologically acceptable excipients.

14. Carboxymethylcysteine and/or a physiologically acceptable salt thereof for use according to claim 13, characterized in that said pharmaceutically
acceptable excipients are selected from emollients, rheological additives, thickening agents, emulsi ers, humectants, buffering agents, antioxidant
agents, chelating agents, moisturizing agents, exfoliating agents, decongestant agents, disinfectant and/or antimicrobial agents, avoring and
colorants.

Description

[0001] The present invention relates to the use of carboxymethylcysteine and/or pharmaceutically acceptable salts thereof to improve the appearance
and the structure of skin affected by stretch marks due to either pregnancy, weight training, weight gain or adolescent growth.
Carboxymethylcysteine is preferably formulated in an appropriate topical composition and may be applied directly on the stretch marks.
BACKGROUND
[0002] Stretch marks are a dis guring condition associated with rapid stretching of the skin, as occurs for example with the abdominal enlargement of
pregnancy. They can be found in children who have become rapidly obese and during the rapid growth of puberty in males and females. They are
common in adult obese women and are mainly located on the breasts, hips, thighs, buttocks, abdomen, and ank. Stretch marks appear as parallel
streaks of red, thinned, glossy skin that over time become whitish and scar-like in appearance. The stretch marks may be slightly depressed and
have a different texture than normal skin. They are virtually impossible to completely and permanently remove. This is because they are the marks
of damaged bers under the skin. The pathogenesis is unknown but probably relates to changes in those structures that provide skin with its
tensile strength. The whole process is triggered by ongoing in ammation processes in the dermis. The actual stretch mark is the consequence of
the dermis stretching to the point of breaking cell-to-cell contact and the bers of the basal membrane. The dermal collagen and elastin ber-
matrix are damaged and dehydrated leaving visible marks or scars (Mitts TF, Jimenez F, Hinek A.: Skin biopsy analysis reveals predisposition to
stretch mark formation. Aesthet Surg J. 2005 Nov-Dec;25(6):593-600). Though stretch marks can rarely be removed completely, there are many
treatments available for the purpose of improving the appearance of existing stretch marks including cosmetic surgery (Lemperle G, Tenenhaus
M, Knapp D, Lemperle SM. The direction of optimal skin incisions derived from striae distensae. Plast Reconstr Surg. 2014 Dec;134(6):1424-34),
laser treatments (de Angelis F, Kolesnikova L, Renato F, Liguori G. Fractional nonablative 1540-nm laser treatment of striae distensae in Fitzpatrick
skin types II to IV: clinical and histological results. Aesthet Surg J. 2011 May;31(4):411-9; Güngör S, Sayilgan T, Gökdemir G, Ozcan D. Evaluation of
an ablative and non-ablative laser procedure in the treatment of striae distensae. Indian J Dermatol Venereol Leprol. 2014 Sep-Oct;80(5):409-12)
and dermabrasion (Hexsel D, Soirefmann M, Porto MD, Schilling-Souza J, Siega C, Dal Forno T. Super cial dermabrasion versus topical tretinoin on
early striae distensae: a randomized, pilot study. Dermatol Surg. 2014 May;40(5):537-44). However, these treatments are rather costly and
downright painful for some, with no assurance that it will indeed work.
[0003] Topical preparations of creams or gels have also been used with controversial results. Some e cacy has been reported by use of tretinoin or
other retinoids, but their use should be avoided in women of childbearing potential due to possible absorption and teratogenic effects (Sarnoff DS.
Therapeutic Update on the Treatment of Striae Distensae. Drugs Dermatol. 2015 Jan 1;14(1):11-12). Keratolytic and exfoliants have also been
reported as useful due their peeling effect. Those products included salicylic and glycolic acid (Ash K, Lord J, Zukowski M, McDaniel DH.
Comparison of topical therapy for striae alba - 20% glycolic acid/0.05% tretinoin versus 20% glycolic acid/10% L-ascorbic acid -. Dermatol Surg.
1998 Aug; 24(8):849-56). The massage with a silicone gel over a period of 6 weeks increased signi cantly the content of collagen in stretch marks
over placebo, and decreased pliability (Ud-Din S, McAnelly SL, Bowring A. et al, A double-blind controlled clinical trial assessing the effect of
topical gels on striae distensae (stretch marks): a non-invasive imaging, morphological and immunohistochemical study. Arch Dermatol Res
(2013) 305:603-617). Most of the above products may cause irritation and e cacy remains controversial (Brennan M, Young G, Devane D. Topical
preparations for preventing stretch marks in pregnancy. Cochrane Database Syst Rev. 2012 Nov 14;11:CD000066).
[0004] Thus, there is still an important medical need for topical preparations which can be effectively and safely used for minimizing stretch marks.
[0005] Carboxymethylcysteine (carbocisteine) is a well-known mucolytic agent that reduces the viscosity of sputum and can be used to help relieve the
symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis by allowing patients to bring up sputum more easily. This
compound and its salts are known in the art ( CN1266681 ) to promote healing of wound and bums when combined with sodium citrate, sodium
laurylsulfate, magnesium laurylsulfate and sodium deoxycholate. WO2008017521A2 discloses using at least a thiolated compound, such as
carboxymethylcysteine, and at least an ester of an organic acid for improving the elasticity of the vagina and of the perineum in pregnant women.
DEFINITIONS
[0006] Unless otherwise de ned, all terms of art, notations and other scienti c terminology used herein are intended to have the meanings commonly
understood by those persons skill in the art to which this disclosure pertains. In some cases, terms with commonly understood meanings are
de ned herein for clarity and/or for ready reference; thus, the inclusion of such de nitions herein should not be construed to represent a
substantial difference over what is generally understood in the art.
[0007] The term "physiologically acceptable excipient" herein refers to a substance devoid of any pharmacological effect of its own and which does not
produce adverse reactions when administered to a mammal, preferably a human. Physiologically acceptable excipients are well known in the art
and are disclosed, for instance in the Handbook of Pharmaceutical Excipients, sixth edition 2009, herein incorporated by reference.
[0008] The term "pharmaceutically acceptable salts" herein refers to those salts or derivatives which possess the biological effectiveness and properties
of the sali ed or derivatized compound and which do not produce adverse reactions when administered to a mammal, preferably a human. The
pharmaceutically acceptable salts may be inorganic or organic salts; examples of pharmaceutically acceptable salts include but are not limited to:
sodium, potassium, calcium, ammonium, lysine, arginine.

https://patents.google.com/patent/EP3081212A1/en?q=carbocisteine&q=marks&oq=carbocisteine+marks 2/8
11/18/2019 EP3081212A1 - Carboxymethylcysteine for topical treatment of stretch marks - Google Patents
[0009] The terms "approximately" and "about" herein refer to the range of the experimental error, which may occur in a measurement.
[0010] The terms "comprising", "having", "including" and "containing" are to be construed as openended terms (i.e. meaning "including, but not limited to")
and are to be considered as providing support also for terms as "consist essentially of", "consisting essentially of", "consist of" or "consisting of".
[0011] The terms "consist essentially of", "consisting essentially of" are to be construed as a semi-closed terms, meaning that no other ingredients which
materially affects the basic and novel characteristics of the invention are included (optional excipients may thus be included).
[0012] The terms "consists of", "consisting of" are to be construed as a closed term.
[0013] The term "oil-gel" herein refers to an anhydrous oil jelli ed with a polymer.
[0014] The term "oil-bath solution" herein refers to an oil and one or more emulsi ers concentrate for extemporaneous emulsion when put in the bath.
DISCLOSURE OF THE INVENTION
[0015] It has now surprisingly been found that carboxymethylcysteine and/or pharmaceutically acceptable salts thereof, besides being able to soften
protein substrates in the mucus and in the skin, are active in scar repair and may be useful to improve the appearance and the structure of the skin
affected by stretch marks. The regular use of carboxymethylcysteine formulated in an appropriate composition suitable for topical application
directly on the stretch marks is able to decrease the thickness, the relief and the pliability of the skin lesions, thus improving both the structure and
the appearance of the concerned skin areas. Moreover, the bene cial effect of carboxymethylcysteine is further increased by the presence of
petrolatum (vaseline) in the composition. The two components act synergistically in repairing the collagen portion of the skin matrix from
broblasts, thus increasing the bene t for the patient by application of compositions containing simultaneously carboxymethylcysteine and
petrolatum.
[0016] An embodiment of the present invention is therefore the use of carboxymethylcysteine and/or a pharmaceutically acceptable salts thereof in the
treatment of stretch marks. Preferably, said pharmaceutically acceptable salt is the lysine salt.
[0017] In an embodiment said stretch marks are located in any part of body or legs. In a further preferred embodiment the stretch marks are due to post-
pregnancy, weight training, weight gain or adolescent growth.
[0018] In a further preferred embodiment, carboxymethylcysteine or a pharmaceutically acceptable salt thereof is used in combination with petrolatum
as emollient.
[0019] In a further embodiment, carboxymethylcysteine or a pharmaceutically acceptable salt thereof, either alone or in combination with petrolatum, is
administered in the form of a pharmaceutical formulation. In a further embodiment, the pharmaceutical formulation is administered topically.
Preferably, said pharmaceutical formulation is in form of ointment, emulsion, cream, lotion, stick, massage oil-gel, bath-oil solution, and is
preferably topically applied by gently massage over the stretch marks for a few minutes, to improve penetration of the ingredients deeply into the
scar tissues.
[0020] In a further embodiment said pharmaceutical formulation has a content in carboxymethylcysteine and/or a pharmaceutically acceptable salt
thereof from 0.1 to 25 % by weight, preferably from 0.5 to 15 % by weight, more preferably from 1.0 to 10 % by weight, with respect to the total
weight of the formulation.
[0021] In a preferred embodiment, the pharmaceutical formulation contains carboxymethylcysteine in form of lysine salt.
[0022] In a further embodiment, said pharmaceutical formulation has a content in petrolatum from 1 to 35 % by weight, preferably from 2.5 to 25 % by
weight, more preferably from 5 to 20% by weight, with respect to the total weight of the formulation
[0023] The pharmaceutical formulation of the present invention may include physiologically acceptable excipients selected from emollients, rheological
additives, thickening agents, emulsi ers, humectants, buffering agents, antioxidant agents, chelating agents, moisturizing agents, exfoliating
agents, decongestant agents, disinfectant and/or antimicrobial agents, avoring and colorants.
[0024] The preferred suitable emollients include oils or other fatty materials, such as prunus amygdalus dulcis oil, petrolatum, para num liquidum,
hydrogenated castor oil, hydrogenated polydecene, octyldodecanol, cera alba, cetostearyl alcohol, sesamum indicum seed oil, dicaprylyl
carbonate, isodecylneopentanoate, C10-18 triglycerides, silicones, such as dimethicone or cyclopenthasiloxane.
[0025] The preferred suitable rheological additives include xanthan gum, carbomer or ammonium acryloyldimethyltaurate/VP copolymer (copolymer of
ammonium acryloyldimethyltaurate and vinylpyrrolidone monomers).
[0026] The preferred suitable thickening agents include silica or polyethylene.
[0027] The preferred suitable emulsi ers include PEG-100 stearate, glyceryl stearate, polyglyceryl-3 methylglucose distearate, olivoyl hydrolyzed wheat
protein, glyceryl oleate, polysorbate 65 or sucrose palmitate.
[0028] The preferred suitable humectants include propylene glycol, glycerin or propanediol.
[0029] In a further embodiment of the present invention, carboxymethylcysteine and/or a pharmaceutically acceptable salt thereof may be used as the
only active principle, or it may be used in combination with one or more active principles such as allantoin, panthenol, betaine, tocopheryl acetate,
tocopherol or lactic acid. According to an embodiment, the formulation consists of or essentially consists of carboxymethylcysteine and/or a
pharmaceutically acceptable salt thereof, one or more physiologically acceptable excipients and optionally one or more active principles selected
from allantoin, panthenol, betaine, tocopheryl acetate, tocopherol or lactic acid.
[0030] The pharmaceutical formulation will be prepared according to conventional techniques. Examples of pharmaceutical formulations prepared
according to the present invention include: ointment, emulsion, cream, lotion, stick, massage oil-gel, bath-oil solution.
[0031] The pharmaceutical formulations and the uses of the present invention will now be more fully described by the following examples. It should,
however, be noted that such examples are given by way of illustration and not of limitation.
EXAMPLES
Example 1
[0032] An ointment, having the following w/w % composition, is prepared: 1) Lysine Carboxymethyl Cysteinate1 5.00% 2) Polyglyceryl-3 Beeswax 7.50% 3)

Prunus Amygdalus Dulcis 12.00% 4) Tocopherol, Lecithin, Ascorbyl palmitate, Citric acid2 0.05% 5) Petrolatum 15.00% 6) Hydrogenated Castor Oil
2.00% 7) Silica 1.50% 8) Para num Liquidum q.s. to 100.00% 1Elastocell® (Lysine Carboxymethyl Cysteinate 30% water solution).
2Aperoxid TLA.

Preparation:
[0033] Para num Liquidum, Polyglyceryl-3 Beeswax, Prunus Amygdalus Dulcis, Aperoxid TLA Petrolatum and Hydrogenated Castor Oil are mixed and
heated at 75 °C - 80°C. When the mass is melted, silica is added under stirring. The mass is mixed to obtain an homogeneous dispersion.
[0034] The melted mass is then cooled at 45°C and Lysine Carboxymethyl Cysteinate is added under vigorous stirring. The resulting mass is cooled to
room temperature under continuous mixing and an homogeneous ointment is obtained.
Example 2

https://patents.google.com/patent/EP3081212A1/en?q=carbocisteine&q=marks&oq=carbocisteine+marks 3/8
11/18/2019 EP3081212A1 - Carboxymethylcysteine for topical treatment of stretch marks - Google Patents
[0035] A clinical study was performed to assess the aesthetic e cacy of the composition according to the Example 1 on reducing stretch marks on the
body and legs of 33 women. The study followed a randomized, open-label, blind-evaluator, intra-individual comparison split-body design. Female
subjects aged from 18 to 65 years with stable weight for at least 2 months signing the informed consent form were included. They were
characterized by stretch marks on the body/legs due to post pregnancy, weight training, weight gain or adolescent growth. All included women
presented two comparable areas with stretch marks on the body/legs or one large area where to allocate the test and the control area. The
composition according to the Example 1 (Prd B) was applied twice a day by a gently massage of 5 minutes on the test area and compared to the
control (untreated) area (Prd A) over a period of 8 weeks. Test and control area (5x5 cm size) were randomized.
[0036] The results were evaluated by means of the OSAS (= Observer Scar Assessment Scale). This scale is considering 6 items, namely vascularity,
pigmentation, thickness, relief, pliability and surface area of the skin lesions, in a 10-point score, where 0= no lesion and 10= maximum imaginable
lesion. For Prd B there was a signi cant decrease of mean thickness from 4.1 at day 1 to 3.6 at day 57, no change for Prd A (p=0.003 between Prd
B and A); mean relief decreased from 4.2 at day 1 to 3.8 at day 57 for Prd B, no change for A (p=0.038); average pliability decreased from 5.2 to 4.4
for Prd B, no change for A (p<0.001). No signi cant differences were found in vascularity, pigmentation or surface area. The overall OSAS score
decreased from 23.8 at day 1 to 22.0 at day 57 for Prd B, while for Prd A it passed from 23.3 at day 1 to 23.6 at day 57 (p<0.001 between Prd B and
A).
[0037] In conclusion, the data of this study put in evidence an effect of the composition according to the Example 1 to decrease severity of stretch marks
when regularly applied for over 8 weeks on the affected skin.
Example 3
[0038] A soft emulsion (cream), having the following w/w % composition, is prepared: 1) Puri ed water q.s. to 100% 2) EDTA 0.10% 3) Betaine 2.00% 4)
Allantoin 0.15% 5) Propylene Glycol 5.00% 6) Ammonium Acryloyldimethyltaurate/VP Copolymer 0.90% 7) Peg-100 Stearate, Glyceryl Stearate
3.00% 8) Cetostearyl Alcohol 1.00% 9) Hydrogenated Polydecene 6.00% 10) Octyldodecanol 2.00% 11) Petrolatum 7.00% 12) Cera Alba 1.00% 13)
Dimethicone 1.00% 14) Tocopherol 0.50% 15) Cyclopentasiloxane 3.00% 16) Lysine Carboxymethyl Cysteinate2 17.00% 17) Preservative q.s. 18)
Buffer (Lactic Acid, Sodium Hydroxide) q.s. 19) Parfum q.s. 2 Elastocell® (Lysine Carboxymethyl Cysteinate 30% water solution).
Preparation:
[0039] In the main vessel, solubilize components 2, 3, 4, 5 in part of water, stirring after each addition. Add component 6 and disperse it thoroughly until
homogeneity. Heat at 70 - 75°C.
[0040] In another vessel combine components 7, 8, 9, 10, 11, 12, 13, 14 and heat at 70°C -75°C under moderate stir. Add the lipophilic phase to the main
vessel and homogenize for about 10 minutes.
[0041] Cool down to 40°C and add on sequence components 15, 16, 17, 18 and 19, homogenizing after each addition for about 3 - 5 minutes.
[0042] Cool down to room temperature under moderate stirring.
Example 4
[0043] A liquid emulsion (lotion), having the following w/w % composition, is prepared: 1) Puri ed water q.s. to 100% 2) EDTA 0.10% 3) Panthenol 0.50%
4) Allantoin 0.15% 5) Propanediol 3.00% 6) Xanthan Gum 0.20% 7) Carbomer 0.15% 8) Polyglyceryl-3 Methylglucose Distearate 1.50% 9) Olivoyl
Hydrolyzed Wheat Protein, Cetearyl Alcohol, Glyceryl Oleate, Glyceryl Stearate, Potassium Hydroxide1 4.50% 10) Sesamum Indicum Seed Oil 4.00%
11) Dicaprylyl Carbonate 3.00% 12) Isodecyl Neopentanoate 2.00% 13) Petrolatum 5.00% 14) Tocopheryl Acetate 0.50% 15) Lysine Carboxymethyl
Cysteinate2 33.50% 16) Buffer (Lactic Acid, Sodium Hydroxide) q.s. 17) Preservative q.s. 18) Parfum q.s. 1 Olivoil Emulsi er (Kalichem).
2Elastocell® (Lysine Carboxymethyl Cysteinate 30% water solution).

Preparation:
[0044] In the main vessel, solubilize components 2, 3, 4, 5 in part of water, stirring after each addition. Add component 6 and disperse it thoroughly until
homogeneity. Add component 7 and disperse it thoroughly using an homogenizer. Heat at 70 - 75°C. In another vessel combine components 8, 9,
10, 11, 12, 13, 14 and heat at 70°C -75°C under moderate stir. Add the lipophilic phase to the main vessel and homogenize for about 10 minutes.
[0045] Cool down to 40°C and add on sequence components 15, 16, 17 and 18, homogenizing after each addition for about 3 - 5 minutes.
[0046] Cool down to room temperature under moderate stirring.
Example 5
[0047] A stick (solid vehicle), having the following w/w % composition, is prepared: 1) C10-18 Triglycerides 85.00% 2) Polysorbate 65 6.00% 3) Tocopheryl
Acetate 0.50% 4) Lysine Carboxymethyl Cysteinate1 3.50% 5) Petrolatum 5.00% 1Elastocell® (Lysine Carboxymethyl Cysteinate 30% water
solution).
Preparation:
[0048] Combine components 1, 2, 3, 5 in a melting pot vessel and melt at 65°C - 70°C while stirring; mix vigorously to homogeneity; cool down slowly
while mixing at 45°C and add component 4, mixing at this temperature for about 5 - 10 minutes; stop the heating and continue mixing until to
reach 35°C - 38C; pour the blend into the mould; start cooling at 5°C for about 10 minutes.
Example 6
[0049] A massage oil-gel, having the following w/w % composition, is prepared: 1) Para num Liquidum, Polyethylene1 76.00% 2) Petrolatum 20.00% 3)

Lysine Carboxymethyl Cysteinate2 4.00% 1Pionier PLW (Hansen & Rosenthal)

2Elastocell® (Lysine Carboxymethyl Cysteinate 30% water solution).

Preparation:
[0050] Combine components 2 and 3. Mix until an homogeneous mass is obtained. Add to component 1 and mix until an homogeneous gel is obtained.
Example 7
[0051] A bath-oil solution, having the following w/w % composition, is prepared: 1) Sucrose Palmitate 4.00% 2) Glycerin 45.00% 3) Puri ed Water 7.00% 4)
Petrolatum 5.00% 5) Hydrogenated Polydecene 20.00% 6) Prunus Amygdalus Dulcis Oil 15.00% 7) Lysine Carboxymethyl Cysteinate1 3.50% 8)
Parfum 0.50% 1Elastocell® (Lysine Carboxymethyl Cysteinate 30% water solution).
Preparation:
[0052] In the main vessel combine components 1, 2, 3 and heat at 80°C while mixing; in a separate vessel combine components 4, 5, 6 and heat at 80°C.
Add to the main vessel very slowly under stirring. Continue mixing until to reach 45°C and add components 7 and 8; mix until room temperature.

Patent Citations (3)

https://patents.google.com/patent/EP3081212A1/en?q=carbocisteine&q=marks&oq=carbocisteine+marks 4/8
11/18/2019 EP3081212A1 - Carboxymethylcysteine for topical treatment of stretch marks - Google Patents

Publication number Priority date Publication date Assignee Title

CN1266681A * 2000-03-15 2000-09-20 王有仁 Carbocisteine composition for promoting healing of wound and burn

WO2008017521A2 2006-08-09 2008-02-14 Polichem Compositions with enhanced elasticizing activity

Sa

US20110250293A1 * 2010-04-11 2011-10-13 Agnes Present invention relates to compositions and methods for the treatment of
Mwangi topical skin conditions, comprising of shea butter, jojoba oil, dihydrogen oxide,
Blomberg Stearic acid, Anhydrous Magnesium Sulphate, Zinc Oxide, Glycerin and a suitable
amount of a Pharmaceutically acceptable carrier, one or both of the following:
Cocoa butter and or petroleum jelly.

Family To Family Citations

* Cited by examiner, † Cited by third party

Non-Patent Citations (13)

Title

"Handbook of Pharmaceutical Excipients", 2009

ASH K; LORD J; ZUKOWSKI M; MCDANIEL DH: "Comparison of topical therapy for striae alba - 20% glycolic acid/0.05% tretinoin versus 20% glycolic acid/10% L-
ascorbic acid", DERMATOL SURG, vol. 24, no. 8, August 1998 (1998-08-01), pages 849 - 56

BRENNAN M; YOUNG G; DEVANE D: "Topical preparations for preventing stretch marks in pregnancy", COCHRANE DATABASE SYST REV., vol. L4, no. LL, November
2012 (2012-11-01), pages CD000066

DE ANGELIS F; KOLESNIKOVA L; RENATO F; LIGUORI G: "Fractional nonablative 1540-nm laser treatment of striae distensae in Fitzpatrick skin types II to IV: clinical
and histological results", AESTHET SURG J, vol. 31, no. 4, May 2011 (2011-05-01), pages 41 1 - 9

ELSAIE M L ET AL: "Striae distensae (Stretch Marks) and different modalities of therapy: An update", DERMATOLOGIC SURGERY, WILEY-BLACKWELL PUBLISHING,
INC, NEW YORK, US, vol. 35, no. 4, April 2009 (2009-04-01), pages 563 - 573, XP002653819, ISSN: 1076-0512, [retrieved on 20090406], DOI: 10.1111/J.1524-
4725.2009.01094.X *

GUNGOR S; SAYILGAN T; GOKDEMIR G; OZCAN D: "Evaluation of an ablative and non-ablative laser procedure in the treatment of striae distensae", INDIAN J
DERMATOL VENEREOL LEPROL, vol. 80, no. 5, September 2014 (2014-09-01), pages 409 - 12

HEXSEL D; SOIREFMANN M; PORTO MD; SCHILLING-SOUZA J; SIEGA C; DAL FORNO T: "Super cial dermabrasion versus topical tretinoin on early striae distensae:
a randomized, pilot study", DERMATOL SURG, vol. 40, no. 5, May 2014 (2014-05-01), pages 537 - 44

K. KORGAVKAR ET AL: "Stretch marks during pregnancy: a review of topical prevention", BRITISH JOURNAL OF DERMATOLOGY, vol. 172, no. 3, 8 February 2015
(2015-02-08), pages 606 - 615, XP055201828, ISSN: 0007-0963, DOI: 10.1111/bjd.13426 *

LEMPERLE G; TENENHAUS M; KNAPP D; LEMPERLE SM: "The direction of optimal skin incisions derived from striae distensae", PLAST RECONSTR SURG., vol. 134,
no. 6, December 2014 (2014-12-01), pages 142 - 34

MITTS TF; JIMENEZ F; HINEK A.: "Skin biopsy analysis reveals predisposition to stretch mark formation", AESTHET SURG J., vol. 25, no. 6, November 2005 (2005-
11-01), pages 593 - 600

S. AL-HIMDANI ET AL: "Striae distensae: a comprehensive review and evidence-based evaluation of prophylaxis and treatment", BRITISH JOURNAL OF
DERMATOLOGY, vol. 170, no. 3, March 2014 (2014-03-01), pages 527 - 547, XP055201813, ISSN: 0007-0963, DOI: 10.1111/bjd.12681 *

SAMOFFDS: "Therapeutic Update on the Treatment of Striae Distensae", DRUGS DERMATOL., vol. 14, no. 1, 1 January 2015 (2015-01-01), pages 11 - 12

UD-DIN S; MCANELLY SL; BOWRING A.: "A double-blind controlled clinical trial assessing the effect of topical gels on striae distensae (stretch marks): a non-
invasive imaging, morphological and immunohistochemical study", ARCH DERMATOL RES, vol. 305, 2013, pages 603 - 617

* Cited by examiner, † Cited by third party

Similar Documents

Publication Publication Date Title

Farage et al. 2007 Structural characteristics of the aging skin: a review

US7682623B2 2010-03-23 Pharmaceutical composition for topical application

ES2242055T3 2005-11-01 Agent with a fat (oil) containing an onion extract, its preparation and use care, prevention or treatment of damaged skin
tissue, particularly scar.

US20060058238A1 2006-03-16 Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making
and using the same

US8512718B2 2013-08-20 Pharmaceutical composition for topical application

https://patents.google.com/patent/EP3081212A1/en?q=carbocisteine&q=marks&oq=carbocisteine+marks 5/8
11/18/2019 EP3081212A1 - Carboxymethylcysteine for topical treatment of stretch marks - Google Patents
US5639740A 1997-06-17 Topical moisturizing composition and method

C Szepietowski et 2005 E cacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment
al. of uremic pruritus: a preliminary study

JP2008512469A 2008-04-24 Compositions and methods for the treatment of skin discoloration

CN1761450A 2006-04-19 Skin preparation for external use characterized by containing sugar derivative of a,a-trehalose

US8653053B2 2014-02-18 Topical skin care composition

KR20030009454A 2003-01-29 SKIN TISSUE REGENERATION PROMOTERS COMPRISING GINSENOSIDE Rb1

KR20140060475A 2014-05-20 Compositions containing anti-acne agents and the use thereof

BRPI0616520A2 2011-06-21 oil-in-water emulsion, process for preparing an emulsion and its use

CA2453823C 2010-12-21 Dermal therapy using phosphate derivatives of electron transfer agents

US20110009374A1 2011-01-13 Method of wound healing and scar modulation

US9849140B2 2017-12-26 Topical compositions comprising bimatoprost and methods for stimulating hair growth therewith

Nussbaum et al. 2006 Cosmetic aspects of pregnancy

Shah et al. 2002 The effects of topical vitamin K on bruising after laser treatment

Kumari et al. 2010 Comparative study of trichloroacetic acid versus glycolic acid chemical peels in the treatment of melasma

CN102283792B 2013-01-16 Natural anti-acne cream

CN103068382A 2013-04-24 Compounds and methods for skin repair

KR20060019540A 2006-03-03 Topical composition for transdermal administration

US20050137164A1 2005-06-23 Diclofenac compositions for the treatment of skin disorders

CN104856892B 2018-06-15 A kind of cosmetics or skin care item preparation rich in growth factor and preparation method thereof

AU2006287746B2 2012-03-01 Novel skin care compositions

Priority And Related Applications

Priority Applications (1)

Application Priority date Filing date Title

EP15163871.5A 2015-04-16 2015-04-16 Carboxymethylcysteine for topical treatment of stretch marks

Applications Claiming Priority (4)

Application Filing date Title

EP15163871.5A 2015-04-16 Carboxymethylcysteine for topical treatment of stretch marks

ARP160100935A 2016-04-07 Carboxymethylcysteine for topical treatment of striae

PCT/EP2016/057972 2016-04-12 Carboxymethylcysteine for topical treatment of stretch marks

TW105111583A 2016-04-14 Carboxymethyl for topical treatment of stretch marks cysteine

Legal Events

Date Code Title Description

2016-10-19 AK Designated contracting states: Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT
LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

2016-10-19 AV Request for validation of the european patent in Extension state: MA

https://patents.google.com/patent/EP3081212A1/en?q=carbocisteine&q=marks&oq=carbocisteine+marks 6/8
11/18/2019 EP3081212A1 - Carboxymethylcysteine for topical treatment of stretch marks - Google Patents

2016-10-19 AX Request for extension of the european patent to Extension state: BA ME

2017-11-29 18D Deemed to be withdrawn Effective date: 20170420

Concepts

machine-extracted Download Filter table

Name Image Sections Count Query match

2-(carboxymethylamino)-3-sulfanylpropanoic acid abstract,claims,description,title 36 0

O
O

HO NH

OH

HS

Skin striae abstract,claims,description,title 34 0

topical abstract,claims,description,title 11 0

salts abstract,claims,description 35 0

mixtures abstract,claims,description 28 0

sodium chloride abstract,claims,description 25 0

growth abstract,claims,description 6 0

pregnancy abstract,claims,description 6 0

weight gain abstract,claims,description 5 0

Petrolatum claims,description 17 0

Petrolatum claims,description 17 0

petrolatum claims,description 17 0

pharmaceutical compositions claims,description 17 0

gels claims,description 10 0

oil claims,description 9 0

chemical substance by application claims,description 6 0

emulsions claims,description 6 0

creams claims,description 5 0

emulsifying agents claims,description 5 0

ointments claims,description 5 0

emollient agent claims,description 4 0

formulation claims,description 4 0

lotions claims,description 4 0

humectant claims,description 3 0

rheological additives claims,description 3 0

thickening agent claims,description 3 0

Antimicrobials claims,description 2 0

antioxidant agent claims,description 2 0

buffering agents claims,description 2 0

chelating agent claims,description 2 0

https://patents.google.com/patent/EP3081212A1/en?q=carbocisteine&q=marks&oq=carbocisteine+marks 7/8
11/18/2019 EP3081212A1 - Carboxymethylcysteine for topical treatment of stretch marks - Google Patents

colorant claims,description 2 0

decongestant claims,description 2 0

desinfective claims,description 2 0

moisturizing claims,description 2 0

pharmaceutic aids claims,description 2 0

Show all concepts from the description section

Data provided by IFI CLAIMS Patent Services

About Send Feedback Public Datasets Terms Privacy Policy

https://patents.google.com/patent/EP3081212A1/en?q=carbocisteine&q=marks&oq=carbocisteine+marks 8/8